**Hematopoietic Cell Transplantation for Acute Myeloid Leukemia**

**DISCLAIMER/INSTRUCTIONS FOR USE**

Medical Policy provides general guidance for applying Blue Cross of Idaho benefit plans (for purposes of Medical Policy, the terms “benefit plan” and “member contract” are used interchangeably). Coverage decisions must reference the member specific benefit plan document. The terms of the member specific benefit plan document may be different than the standard benefit plan upon which this Medical Policy is based. If there is a conflict between a member specific benefit plan and the Blue Cross of Idaho’s standard benefit plan, the member specific benefit plan supersedes this Medical Policy. Any person applying this Medical Policy must identify member eligibility, the member specific benefit plan, and any related policies or guidelines prior to applying this Medical Policy. Blue Cross of Idaho Medical Policies are designed for informational purposes only and are not an authorization, explanation of benefits or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member specific benefit plan coverage. Blue Cross of Idaho reserves the sole discretionary right to modify all its Policies and Guidelines at any time. This Medical Policy does not constitute medical advice.

**POLICY**

Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat:

- poor- to intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) (see Policy Guidelines section for information on risk stratification); or
- AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy; or
- AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy; or
- AML in patients who have relapsed following a prior autologous HCT, but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure.

Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in patients who are in complete marrow and extramedullary remission (CR1 or beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines section).

Autologous HCT may be considered medically necessary to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy in patients who are not candidates for allogeneic HCT.

Allogeneic and autologous HCT are investigational in patients not meeting any of the above criteria.
POLICY GUIDELINES

Primary refractory acute myeloid leukemia (AML) is defined as leukemia that does not achieve a complete remission after conventionally dosed (nonmarrow ablative) chemotherapy.

In the French-American-British criteria, the classification of AML is solely based on morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.

Clinical features that predict poor outcomes of AML therapy include, but are not limited to, the following:

- Treatment-related AML (secondary to prior chemotherapy and/or radiotherapy for another malignancy)
- AML with antecedent hematologic disease (eg, myelodysplasia)
- Presence of circulating blasts at the time of diagnosis
- Difficulty in obtaining first complete remission with standard chemotherapy
- Leukemias with monocytoid differentiation (French-American-British classification M4 or M5).

The newer, currently preferred, World Health Organization classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers. It attempts to construct a classification that is universally applicable and prognostically valid. The World Health Organization system was adapted by National Comprehensive Cancer Network to estimate individual patient prognosis to guide management, as shown in Table PG1.

Table PG1. Risk Status of AML Based on Cytogenetic and Molecular Factors

<table>
<thead>
<tr>
<th>Risk Status</th>
<th>Cytogenetic Factors</th>
<th>Molecular Abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>Inv16, t(8;21), t(16;16)</td>
<td>Normal cytogenetics with isolated NPM1 variant</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Normal +8 only, t(9;11) only Other abnormalities not listed with better-risk and poor-risk cytogenetics</td>
<td>c-KIT variant in patients with t(8;21) or inv16</td>
</tr>
<tr>
<td>Poor</td>
<td>Complex (≥3 abnormalities) -5, -7, 5q-, 7q-, +8, inv3, t(3;3), t(6;9), t(9;22) Abnormalities of 11q23, excluding t(9;11)</td>
<td>Normal cytogenetics with isolated FLT3-ITD variant</td>
</tr>
</tbody>
</table>

AML: acute myeloid leukemia; ITD: internal tandem duplication.

The relative importance of cytogenetic and molecular abnormalities in determining prognosis and guiding therapy is under investigation.

The ideal allogeneic donors are human leukocyte antigen–identical siblings, matched at the human leukocyte antigen-A, -B, and -DR loci (6 of 6). Related donors mismatched at 1 locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, for which there usually is sharing of only 3 of the 6 major histocompatibility antigens. Most patients will have such a donor; however, the risk of graft-versus-host
disease and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.

Coding

In 2003, CPT centralized codes describing allogeneic and autologous hematopoietic cell support services to the hematology section (CPT 38204-38242). Not all codes are applicable for each stem cell support procedure. For example, Plans should determine if cryopreservation is performed. A range of codes describe services associated with cryopreservation, storage, and thawing of cells (38208-38215).

CPT 38208 and 38209 describe thawing and washing of cryopreserved cells.

CPT 38210-38214 describe certain cell types being depleted.

CPT 38215 describes plasma cell concentration.

BENEFIT APPLICATION

BLUECARD/NATIONAL ACCOUNT ISSUES

For indications considered investigational, the following considerations may supersede this policy:

- State mandates requiring coverage for hematopoietic cell transplantation offered as part of clinical trials of autologous bone marrow transplantation approved by the National Institutes of Health.
- Some Plans may participate in voluntary programs offering coverage for patients participating in clinical trials (approved by the National Institutes of Health) dealing with cancer and chemotherapies, including autologous hematopoietic cell transplantation.
- Some contracts or certificates of coverage (eg, Federal Employee Program) may include specific conditions in which autologous hematopoietic cell transplantation would be considered eligible for coverage.

BACKGROUND

Acute Myeloid Leukemia

AML, also called acute nonlymphocytic leukemia, AML refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. AML is characterized by a proliferation of myeloblasts, coupled with low production of mature red blood cells, platelets, and often non-lymphocytic white blood cells (granulocytes, monocytes). Clinical signs and symptoms are associated with neutropenia, thrombocytopenia, and anemia. The incidence of AML increases with age, with a median of 67 years. Approximately 21380 new cases are diagnosed annually.¹

Pathophysiology

The pathogenesis of AML is unclear. It can be subdivided by similarity to different subtypes of normal myeloid precursors using the French-American-British classification system. This system classifies leukemias from M0 to M7, based on morphology and cytochemical staining, with immunophenotypic data in some instances. The World Health Organization subsequently incorporated clinical, immunophenotypic, and a wide variety of cytogenetic abnormalities that occur in 50% to 60% of AML cases into a classification system that can be used to guide treatment according to prognostic risk categories.

Classification
The World Health Organization system recognizes five major subcategories of AML: (1) AML with recurrent genetic abnormalities; (2) AML with multilineage dysplasia; (3) therapy-related AML and myelodysplasia; (4) AML not otherwise categorized; and (5) acute leukemia of ambiguous lineage. AML with recurrent genetic abnormalities includes AML with t(8;21) (q22;q22), inv16 (p13:q22) or t(16;16) (p13;q22), t(15;17) (q22;q12), or translocations or structural abnormalities involving 11q23. Younger patients may exhibit t(8;21) and inv16 or t(16;16). AML patients with 11q23 translocations include 2 subgroups: AML in infants and therapy-related leukemia. Multilineage dysplasia AML must exhibit dysplasia in 50% or more of the cells of 2 or more lineages, which is associated with cytogenetic findings that include −5, 5q−, −7, 7q−, +8, +9, +11, 11q−, 12p−, -18, +19, 20q−, +21, and other translocations. AML not otherwise categorized includes a disease that does not fulfill criteria for the other groups and essentially reflects the morphologic and cytochemical features and maturation level criteria used in the French-American-British classification, except for the definition of AML as having a minimum of 20% (as opposed to 30%) blasts in the marrow. AML of ambiguous lineage is diagnosed when blasts lack sufficient lineage-specific antigen expression to classify as myeloid or lymphoid.

**Genetic Abnormalities**

Molecular studies have identified a number of genetic abnormalities that can also be used to guide prognosis and management of AML. Cytogenetically normal AML is the largest defined subgroup of AML, comprising approximately 45% of all AML cases. Despite the absence of cytogenetic abnormalities, these cases often have genetic variants that affect outcomes, six of which have been identified. The FLT3 gene that encodes FMS-like receptor tyrosine kinase 3, a growth factor active in hematopoiesis, is mutated in 33% to 49% of cytogenetically normal AML cases; among those, 28% to 33% consist of internal tandem duplications, 5% to 14% are missense variants in exon 20 of the tyrosine kinase activation loop, and the rest are single nucleotide variants in the juxtamembrane domain. All FLT3 variants result in a constitutively activated protein and confer a poor prognosis. Several pharmaceutical agents that inhibit the FLT3 tyrosine kinase are under investigation.

**Treatment**

Complete remission can be achieved initially using induction therapy, consisting of conventional doses of combination chemotherapy. A complete response is achieved in 60% to 80% of adults younger than 60 years of age and 40% to 60% in patients older than 60 years of age. However, the high incidence of disease relapse has prompted research into a variety of post-remission (consolidation) strategies, typically using high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) or high-dose or reduced-intensity chemotherapy with allogeneic HCT (allo-HCT). The two treatments—autologous HCT and allo-HCT—represent two different strategies. The first, autologous HCT, is a “rescue,” but not a therapeutic procedure; the second, allo-HCT, is a “rescue” plus a therapeutic procedure.

**Hematopoietic Cell Transplantation**

HCT is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in detail in evidence review 7.01.50.
Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT; however, immunologic compatibility between donor and patient is critical for achieving a good outcome with allo-HCT. Immunologic compatibility is established by classifying human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

**Conventional Conditioning for HCT**

The conventional practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation; this is performed at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect of this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that is mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are medically fit to tolerate substantial adverse events that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increase susceptibility to opportunistic infections. The immune reactivity between donor T-cells and malignant cells is responsible for the GVM effect; it also leads to acute and chronic GVHD.

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy (with or without radiation) to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed when the patient’s disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

**Reduced-Intensity Conditioning for Allo-HCT**

RIC refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is two-fold: to reduce disease burden, and to minimize treatment-related morbidity and nonrelapse mortality when the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of nonrelapse mortality and relapse due to residual disease. RIC regimens can be viewed as a continuum—from nearly totally myeloablative to minimally myeloablative with lymphoablation—because it tailors its intensity to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this evidence review, RIC refers to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

A 2015 review in the *New England Journal of Medicine* has summarized recent advances in the classification of AML, the genomics of AML and prognostic factors, and current and new treatments.2
Regulatory Status
The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

RATIONALE
This evidence review was created in December 1999 and has been updated regularly with searches of the MEDLINE database. The most recent literature review was performed through October 30, 2018.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function-including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Hematopoietic cell transplantation (HCT) has been investigated as consolidation therapy for patients whose disease enters complete remission following initial induction treatment. It also is used as salvage therapy in patients who experience disease relapse or have disease refractory to induction chemotherapy. This evidence review discusses the following uses and conditions of HCT: consolidation therapy with allogeneic HCT (allo-HCT) during first complete remission (CR1), salvage therapy for refractory acute myeloid leukemia (AML), therapy for relapsed AML, reduced-intensity conditioning (RIC), and consolidation therapy with autologous HCT.

Allo-HCT for AML
Clinical Context and Therapy Purpose
Allo-HCT is an option for post-remission or consolidation therapy in AML. The purpose of post-remission therapy is to destroy undetectable leukemia cells remaining after induction chemotherapy.

The question addressed in this evidence review is: does allo-HCT improve health outcomes in patients with AML?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population(s) of interest are those with:

1. cytogenetic or molecular intermediate- or poor-risk AML in first complete remission;
2. AML refractory to standard induction chemotherapy;
3. AML who relapsed after standard induction chemotherapy-induced first complete remission;
4. cytogenetic or molecular intermediate- or poor-risk AML in remission and cannot tolerate myeloablative conditioning (MAC).

**Interventions**

The therapy being considered is allo-HCT.

**Comparators**

Consolidation chemotherapy and autologous HCT are also options for post-remission therapy.

**Outcomes**

The general outcomes of interest are survival outcomes (overall and disease-free survival), relapse rates, and treatment-related morbidity.

**Timing**

The median survival of patients with AML varies with several known prognostic factors related to patient and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for patients with AML without chemotherapy or HCT is less than 10 months; the median survival in patients with chemotherapy but without HCT is approximately 20 months.

**Setting**

AML is treated in the secondary care setting by oncologists and hematologists.

**Allo-HCT for Chemotherapy-Responsive Consolidation**

**Systematic Reviews**

A 2015 meta-analysis examined prospective trials of adults with intermediate-risk AML in CR1 who underwent HCT. The analysis included 9 prospective, controlled studies that enrolled 1950 patients between the years 1987 and 2011 (sample range, 32-713 patients). Allo-HCT was associated with significantly better relapse-free survival (RFS), overall survival (OS), and relapse rate than autologous HCT and/or chemotherapy (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.48 to 0.95; HR=0.76; 95% CI, 0.61 to 0.95; HR=0.58; 95% CI, 0.45 to 0.75, respectively). Treatment-related mortality was significantly higher following allo-HCT than autologous HCT (HR=3.09; 95% CI, 1.38 to 6.92). However, a subgroup analysis, which used updated criteria to define intermediate-risk AML, showed no OS benefit for allo-HCT over autologous HCT (HR=0.99; 95% CI, 0.70 to 1.39).

A 2009 systematic review incorporated data from 24 trials involving 6007 patients who underwent allo-HCT in CR1. Among the total, 3638 patients were stratified and analyzed according to cytogenetic risk (547 good-, 2499 intermediate-, 592 poor-risk patients with AML) using a fixed-effects model. Compared with either autologous HCT or additional consolidation chemotherapy, the HR for OS among poor-risk patients across 14 trials was 0.73 (95% CI, 0.59 to 0.90; p<0.01); among intermediate-risk patients across 14 trials, the HR for OS was 0.83 (95% CI, 0.74 to 0.93; p<0.01); and among good-risk patients across 16 trials, the HR for OS was 1.07 (95% CI, 0.83 to 1.38; p=0.59). Interstudy heterogeneity was not significant in any of these analyses. Results for disease-free survival (DFS) were very similar to those for OS in this
analysis. These results are in line with those from another meta-analysis\textsuperscript{6} on the use of allo-HCT as consolidation therapy for AML.

A 2005 meta-analysis of allo-HCT in patients with AML in CR1 pooled data from 5 studies (total n=3100 patients).\textsuperscript{5} Among those patients, 1151 received allo-HCT, and 1949 were given alternative therapies including chemotherapy and autologous HCT. All studies employed natural randomization based on donor availability and intention-to-treat analysis, with OS and DFS as outcomes of interest. This analysis showed a significant advantage for allo-HCT regarding OS for the entire cohort (fixed-effects model HR=1.17; 95% CI, 1.06 to 1.30; p=0.003; random-effects model HR=1.15; 95% CI, 1.01 to 1.32; p=0.037) even though none of the individual studies did so. Meta-regression analysis showed the effect of allo-HCT on OS differed depending on the cytogenetic risk groups of patients, suggesting a significant benefit for poor-risk patients (HR=1.39, 95% CI not reported), an indeterminate benefit for intermediate-risk cases, and no benefit in better-risk patients compared with alternative approaches. Reviewers cautioned the compiled studies used different definitions of risk categories than other groups (eg, SWOG, Medical Research Council, European Organisation for Research and Treatment of Cancer, Gruppo Italiano Malattie Ematologiche dell’ Adulto)\textsuperscript{7} Although the statistical power of the meta-regression analysis was limited by small numbers of cases, the results of this meta-analysis are supported in general by data from other reviews.\textsuperscript{8,9,10,11}

Evidence from the meta-analysis suggests patients with better prognosis (as defined by cytogenetics) may not realize a significant survival benefit with allo-HCT in CR1 that outweighs the risk of associated morbidity and nonrelapse mortality. However, there is considerable genotypic heterogeneity within the three World Health Organization cytogenetic prognostic groups that complicates generalization of clinical results based only on cytogenetics.\textsuperscript{12} For example, patients with better prognosis disease (eg, core-binding factor AML) based on cytogenetics, and a variant in the KIT gene of leukemic blast cells, do just as poorly with post-remission standard chemotherapy as patients with cytogenetically poor-risk AML.\textsuperscript{13} Similarly, patients with cytogenetically normal AML (intermediate prognosis disease) can be subcategorized into groups with better or worse prognosis based on the mutational status of the nucleophosmin gene (NPM1) and the FLT3 gene (the FLT3 gene, as defined in the Background section, is a gene that encodes FMS-like receptor tyrosine kinase 3, a growth factor active in hematopoiesis). Thus, patients with variants in NPM1 but without FLT3 internal tandem duplications have post-remission outcomes with standard chemotherapy that are similar to those with better prognosis cytogenetics; in contrast, patients with any other combination of variants in those genes have outcomes similar to those with poor prognosis cytogenetics.\textsuperscript{14} It follows that, because the earlier clinical trials compiled in the meta-analysis described here did not account for genotypic differences that affect prognosis and alter outcomes, it is difficult to use the primary trial results to draw conclusions on the role of allo-HCT in different patient risk groups.

A meta-analysis by Buckley et al (2017) evaluated the relation between minimal residual disease (MRD) at the time of HCT and posttransplantation outcomes.\textsuperscript{15} The literature search, conducted through June 2016, identified 19 studies (total n=1431 patients) for inclusion. Risk of bias was assessed using a modified version of the Quality of Prognostic Studies instrument, which focused on: prognostic factor measurement, study confounding, and statistical analysis and reporting. Five studies were considered at high-risk for bias, nine were at moderate-risk, and five were at low-risk. The following variables were collected from each study: age, follow-up, adverse-risk cytogenetics, conditioning type (myeloablative or reduced-intensity), MRD detection method, and survival. Reviewers reported that the presence of MRD at the time of transplantation was associated with higher relapse and mortality. This association was seen regardless of patient age and type of conditioning, which suggests that an intense conditioning regimen may not be able to overcome the adverse impact of MRD.
Prospective Studies

A 2014 study compared outcomes of 185 matched pairs from a large multicenter trial (AMLCG99). Patients younger than 60 years of age who underwent allo-HCT in CR1 were matched to patients who received conventional post-remission chemotherapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in CR1. In the overall pairwise-compared AML population, the projected 7-year OS rate was 58% for allo-HCT and 46% for the conventional post-remission treatment group (p=0.037). The RFS rate was 52% in the allo-HCT group and 33% in the control group (p<0.001). OS was significantly longer for allo-HCT patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, post-remission therapy was an independent factor for OS (HR=0.66; 95% CI, 0.49 to 0.89 for allo-HCT vs conventional chemotherapy) among age, cytogenetics, and bone marrow blasts after the first induction cycle.

Retrospective Studies

Heidrich et al (2017) conducted retrospective analyses of subgroups from 2 prospective clinical trials, including 497 patients with intermediate-risk AML who did not present with NPM1, CEBPA, or FLT3 internal tandem duplication variants. During the initial analysis (donor vs no-donor), RFS rates were better for patients who had an available sibling donor (n=83) than for those who lacked a matched sibling donor (49% vs 26%; HR=0.5; 95% CI, 0.3 to 0.9; p=0.02); a similar improvement was seen for OS, although not statistically significant (p=0.08). The authors also conducted a time-dependent multivariate analysis to account for the significantly longer time-from-CR1 observed in patients treated with allo-HCT (median, 115 days) compared with those treated with post-remission chemotherapy (median, 78 days; p<0.001). Rates of OS after 5 years were superior for the group who received allo-HCT than for those receiving chemotherapy (OS, 66% vs 46%, respectively; HR=0.58; 95% CI, 0.37 to 0.9; p=0.02), as were rates of RFS (5-year RFS, 55% vs 31%; HR=0.51; 95% CI, 0.34 to 0.76; p=0.001). The investigators acknowledged that 38% of the group assigned to post-remission chemotherapy received allo-HCT following a relapse, which might have contributed to a crossover effect.

Section Summary: Allo-HCT for Chemotherapy-Responsive Consolidation

Evidence for the use of allo-HCT for patients with AML in CR1 consists of RCTs and matched cohort studies. Some studies have compared allo-HCT with autologous HCT or with post-remission chemotherapy. OS rates and DFS rates were favorable for allo-HCT compared with conventional chemotherapy. In a paired comparison with patients receiving chemotherapy, patients receiving allo-HCT experienced significantly higher RFS rates. Two retrospective studies analyzed subgroups of allo-HCT patients who did not present with several common genetic variants or who presented with hyperleukocytosis. Survival rates appear to be associated with the presence of MRD and cytogenetic prognosis group.

Allo-HCT for AML Refractory to Chemotherapy

Conventional dose induction chemotherapy will not produce remission in 20% to 40% of patients with AML, connoting refractory AML. An allo-HCT using a matched related donor or matched unrelated donor represents the only potentially curative option for these patients. In several retrospective studies, OS rates have ranged from 30% at 3 years to 13% at 5 years, although this procedure is accompanied by nonrelapse mortality rates of 25% to 62% in this setting. For patients who lack a suitable donor (matched related donor or matched unrelated donor), alternative treatments include salvage chemotherapy with high-dose cytarabine or etoposide-based regimens, monoclonal antibodies (eg, gemtuzumab ozogamicin), multidrug resistance modulators, and investigational agents.
Because it is likely that stem cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, upfront autologous HCT has no role in patients who fail induction therapy.\textsuperscript{18}

**Section Summary: Allo-HCT for AML Refractory to Chemotherapy**

Evidence for the use of allo-HCT for individuals with primary AML refractory to chemotherapy consists of retrospective studies compiled from data from phase 3 trials and registries. OS rate estimates are 30% at 3 years and 13% at 5 years; however, the procedure is accompanied by high rates of nonrelapse mortality (estimated range, 25%-62%). Nonetheless, these results may provide a clinically meaningful benefit for such patients who do not have other treatment options. Autologous HCT is not recommended for patients who have failed induction therapy, because malignant cells may be included in the stem cell preparation process.

**Allo-HCT for Relapsed AML After Chemotherapy**

Most patients with AML will experience disease relapse after attaining a CR1.\textsuperscript{7} Conventional chemotherapy is not curative in most patients following disease relapse, even if a second complete remission (CR2) can be achieved.

A study by Breems et al (2005) evaluated retrospective data from 667 patients who had relapsed, among a total of 1540 patients entered in 3, phase 3 trials who had received HCT during CR1. The analysis suggested that use of allo-HCT among relapsed patients can produce 5-year OS rates of 26% to 88%, depending on cytogenetic risk stratification.\textsuperscript{20}

Allo-HCT is often performed as salvage therapy for patients who have relapsed after conventional chemotherapy or autologous HCT.\textsuperscript{10} The decision to attempt reinduction to allo-HCT is based on the availability of a suitable stem cell donor and the likelihood of achieving remission, the latter being a function of cytogenetic risk group, duration of CR1, and the patient’s health status. Registry data have shown DFS rates of 44% using sibling allografts and 30% with matched unrelated donor allografts at 5 years for patients transplanted in CR2, and DFS rates of 35% to 40% using sibling transplants and 10% with matched unrelated donor transplants for patients with induction failure or in relapse following HCT.\textsuperscript{19}

In a retrospective chart review, Frazer et al (2017) assessed characteristics that might predict OS, relapse rate, and nonrelapse mortality of HCT in patients with relapsed AML.\textsuperscript{21} Data were abstracted from 55 consecutive patients who underwent allo-HCT for AML in CR2. OS rates at 1, 3, and 5 years posttransplant were 60%, 45%, and 37%, respectively. None of the following pretransplant variables was significantly associated with OS, relapse rate, or nonrelapse mortality: duration of first remission, patient age, cytogenetic risk category, post myelodysplastic syndrome, conditioning regimen, or donor type. Limitations of the study were its small sample size and selection parameters that included transplantations conducted across 21 years.

**Section Summary: Allo- or Autologous HCT for Relapsed AML After Chemotherapy**

Evidence on the use of HCT for individuals with relapsed AML includes retrospective chart reviews compiling data from phase 3 trials and registries. DFS rates ranged from 30% to 44% depending on the source of transplantation cells, and OS rates ranged from 26% to 88% depending on risk stratification. Because reinduction chemotherapy may be associated with high morbidity and mortality, HCT may be considered.

**Allo-HCT with RIC**
A body of evidence is accruing from clinical studies that RIC with allo-HCT may be used for consolidation therapy in patients with AML.\textsuperscript{22,23,24,25,26,27,28,29,30,31,32,33}

**Systematic Reviews**

A systematic review and meta-analysis by Rashidi et al (2016) calculated OS and RFS for patients older than 60 years of age with AML who underwent RIC HCT.\textsuperscript{34} A literature search, conducted through September 2015, identified 13 studies (total n=749 patients) for inclusion. Pooled estimates for RFS at 6 months, 1 year, 2 years, and 3 years were 62% (95% CI, 54% to 69%), 47% (95% CI, 42% to 53%), 44% (95% CI, 33% to 55%), and 35% (95% CI, 26% to 45%), respectively. Pooled estimates for OS at 6 months, 1 year, 2 years, and 3 years were 73% (95% CI, 66% to 79%), 58% (95% CI, 50% to 65%), 45% (95% CI, 35% to 54%), and 38% (95% CI, 29% to 48%), respectively.

A 2014 meta-analysis compared RIC with myeloablative conditioning (MAC) regimens for allo-HCT in patients with AML.\textsuperscript{35} The analysis included 23 clinical trials reported between 1990 and 2013, with approximately 15000 adults. Eleven studies included AML and myelodysplastic syndrome, and five included AML only. A subanalysis from 13 trials in patients with AML or myelodysplastic syndrome revealed that OS was comparable in patients who received either RIC or MAC transplants, and the 2-year or less and 2-year or greater OS rates were equivalent between both conditioning groups. The 2- to 6-year progression-free survival, nonrelapse mortality, and acute and chronic graft-versus-host disease (GVHD) rates were reduced after RIC HCT, but the relapse rate was increased. Similar outcomes were observed regardless of disease status at transplantation. Among the RIC HCT recipients, survival rates were superior if patients were in complete remission at transplantation.

**Randomized Controlled Trials**

A randomized comparative trial in matched patient groups compared the net health benefit of allo-HCT with RIC or with MAC.\textsuperscript{36,37,38} In this phase 3 trial, patients (18-60 years) were randomized to 4 doses of RIC (n=99) at 2 gray of total body irradiation plus fludarabine 150 mg/m\textsuperscript{2}, or to 6 doses of standard conditioning (n=96) at 2 gray of total body irradiation plus cyclophosphamide 120 mg/kg. All patients received cyclosporine and methotrexate as prophylaxis against GVHD. The primary endpoint was the incidence of nonrelapse mortality analyzed in the intention-to-treat population. This unblinded trial was stopped early because of slow accrual of patients. The incidence of nonrelapse mortality did not differ between the RIC and standard conditioning groups (cumulative incidence at 3 years, 13% [95% CI, 6% to 21%] vs 18% [95% CI, 10% to 26%]; HR=0.62; 95% CI, 0.30 to 1.31, respectively). Relapse cumulative incidence at 3 years was 28% (95% CI, 19% to 38%) in the RIC group and 26% (95% CI, 17% to 36%; HR=1.10; 95% CI, 0.63 to 1.90) in the standard conditioning group. The DFS rates at 3 years were 58% (95% CI, 49% to 70%) in the RIC group and 56% (95% CI, 46% to 67%; HR=0.85; 95% CI, 0.55 to 1.32) in the standard conditioning group. The OS rates at 3 years were 61% (95% CI, 50% to 74%) in the RIC group and 58% (95% CI, 47% to 70%; HR=0.77; 95% CI, 0.48 to 1.25) in the standard conditioning group. No outcomes differed significantly between groups. Grade 3 and 4 oral mucositis was less common in the RIC group (50 patients) than in the standard conditioning group (73 patients); the frequency of other adverse events such as GVHD and increased concentrations of bilirubin and creatinine did not differ significantly between groups.

A phase 2 single-center, randomized toxicity study (2013) compared MAC with RIC in patients who received allo-HCT to treat AML.\textsuperscript{39} Adults 60 years of age or younger with AML were randomized (1:1) to treatment with RIC (n=18) or MAC (n=19) for allo-HCT. A maximum median mucositis grade of 1 was observed in the RIC group compared with grade 4 in the MAC group (p<0.001). Hemorrhagic cystitis occurred in 8 (42%) of the patients in the MAC group and none (0%) in the RIC group (p<0.01). Results of renal and hepatic tests did not differ significantly between groups. RIC-treated patients had faster
platelet engraftment ($p<0.01$) and required fewer erythrocyte and platelet transfusions ($p<0.001$) and less total parenteral nutrition than those treated with MAC ($p<0.01$). Cytomegalovirus infection was more common in the MAC group (14/19) than in the RIC group (6/18; $p=0.02$). Donor chimerism was similar in the 2 groups for CD19 and CD33 but was delayed for CD3 in the RIC group. Five-year treatment-related morbidity was approximately 11% in both groups, and rates of relapse and survival did not differ significantly. Patients in the MAC group with intermediate cytogenetic AML had a 3-year survival rate of 73% compared with 90% among those in the RIC group.

**Comparative Trials**

In a 2016 comparative study by the European Society for Blood and Marrow Transplantation, long-term survival was evaluated among patients with AML who underwent allo-HCT with RIC or with MAC regimens.\textsuperscript{40} Data from 701 patients receiving MAC and 722 patients receiving RIC were analyzed. Survival, relapse, and GVHD rates are summarized in Table 1. In a multivariate analysis, the following factors predicted nonrelapse mortality: RIC, age older than 55 years, advanced disease, and female donor to male recipient. Factors predicting chronic GVHD (a surrogate outcome for quality of life) were: in vivo T-cell depletion, advanced disease, and peripheral blood cell transplantation.

**Table 1. Comparison of 10-Year Outcomes for RIC and MAC Regimens in Patients Undergoing Allo-HCT**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>RIC (n=722) Rate (95% CI), %</th>
<th>MAC (n=701) Rate (95% CI), %</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonrelapse mortality</td>
<td>20 (17 to 24)</td>
<td>35 (31 to 39)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Relapse</td>
<td>48 (44 to 52)</td>
<td>34 (31 to 38)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leukemia-free survival, overall</td>
<td>32 (28 to 35)</td>
<td>31 (27 to 35)</td>
<td>0.57</td>
</tr>
<tr>
<td>Age 50-55 y</td>
<td>40 (33 to 46)</td>
<td>36 (32 to 41)</td>
<td>0.32</td>
</tr>
<tr>
<td>Age &gt;55 y</td>
<td>20 (14 to 26)</td>
<td>28 (24 to 32)</td>
<td>0.02</td>
</tr>
<tr>
<td>Overall survival</td>
<td>35 (32 to 39)</td>
<td>33 (29 to 37)</td>
<td>0.57</td>
</tr>
<tr>
<td>GVHD-free, relapse-free survival</td>
<td>21 (18 to 24)</td>
<td>22 (18 to 25)</td>
<td>0.79</td>
</tr>
</tbody>
</table>

Adapted from Shimoni et al (2016).\textsuperscript{40} allo-HCT: allogeneic hematopoietic cell transplantation; CI: confidence interval; GVHD: graft-versus-host disease; MAC: myeloablative conditioning; RIC: reduced-intensity conditioning.

In a comparative study by Bitan et al (2014), outcomes were compared for children with AML who underwent allo-HCT using RIC regimens or MAC regimens.\textsuperscript{41} A total of 180 patients were evaluated; 39 underwent RIC and 141 received MAC regimens. Univariate and multivariate analyses showed no significant differences in the rates of acute and chronic GVHD, leukemia-free survival, and OS between treatment groups. The 5-year probabilities of OS with RIC and MAC regimens were 45% and 48%, respectively ($p=0.99$). Moreover, relapse rates were similar for RIC (39%) and MAC regimens (39%; $p=0.95$), and recipients of MAC regimens were not at a higher risk for transplant-related mortality (16%) than recipients of RIC regimens (16%; $p=0.73$).

**Noncomparative Studies**

In a phase 2 study by Devine et al (2015), 114 patients ages 60 to 74 years with AML in CR1 were treated with RIC and allo-HCT.\textsuperscript{42} Patients were followed for two years. The primary endpoint was DFS, and secondary endpoints were nonrelapse mortality, GVHD, relapse, and OS. Two years after...
transplantation, the following rates were recorded: DFS, 42% (95% CI, 33% to 52%); OS, 48% (95% CI, 39% to 58%); nonrelapse mortality, 15% (95% CI, 8% to 21%); grades 2, 3, or 4 acute GVHD, 10% (95% CI, 4% to 15%); grades 2, 3, or 4 chronic GVHD, 28% (95% CI, 19% to 36%); and cumulative incidence of relapse, 44% (95% CI, 35% to 53%).

Section Summary: Allo-HCT with RIC

Evidence for the use of RIC and allo-HCT to treat patients with AML consists of two RCTs, two meta-analyses, and numerous comparatives and noncomparative studies. In general, compared with MAC, RIC has comparable survival estimates (leukemia-free, overall), though relapse rates appear higher among patients receiving RIC in some studies.

Autologous HCT for AML

Clinical Context and Therapy Purpose

For patients with AML in complete remission without an acceptable HLA donor, autologous HCT is an option for consolidation therapy.

The question addressed in this evidence review is: does autologous HCT improve health outcomes in patients with AML who are not candidates for allo-HCT?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant population(s) of interest are those without suitable allo-HCT donor.

Interventions

The therapy being considered is autologous HCT.

Comparators

Consolidation chemotherapy is an option for post-remission therapy.

Outcomes

The general outcomes of interest are survival outcomes (OS and DFS), relapse rates, and treatment-related morbidity.

Timing

The median survival of patients with AML varies with several known prognostic factors related to patient and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for patients with AML without chemotherapy or HCT is less than 10 months; the median survival in patients with chemotherapy but without HCT is approximately 20 months.\(^3\)

Setting

AML is treated in the secondary care setting by oncologists and hematologists.

Autologous HCT for Chemotherapy-Responsive Consolidation

Systematic Reviews

A meta-analysis published by Nathan et al (2004) compared survival outcomes for autologous HCT in CR1 with standard chemotherapy or no further treatment in AML patients ages 15 to 55 years.\(^4\) Two types of studies were eligible: (1) prospective cohort studies in which patients with an available sibling donor were offered allo-HCT (biologic randomization) with random assignment of all others to
autologous HCT or chemotherapy (or no further treatment); and (2) randomized trials that compared autologous HCT with chemotherapy in all patients. Among a total of 4058 patients included in 6 studies, 2989 (74%) achieved CR1; 1044 (26%) were randomized to HCT (n=524) or to chemotherapy (n=520). Of the five studies for which OS data were available, outcomes with autologous HCT were better in three, and outcomes with chemotherapy were better in two. None of the differences were statistically significant, nor was the pooled estimate (fixed-effects model survival probability ratio, 1.01; 95% CI, 0.89 to 1.15; p=0.86). In all 6 studies, DFS was numerically superior using autologous HCT compared with chemotherapy (or no further treatment), but only one reported a statistically significant DFS probability associated with autologous HCT. The pooled estimate for DFS showed a statistically significant probability in favor of autologous HCT at 48 months posttransplant (fixed-effects model survival probability ratio, 1.24; 95% CI, 1.06 to 1.44; p=0.006). This review comprised studies performed between 1984 and 1995, during which transplant protocols and patient management evolved significantly, particularly compared with current care.

A second meta-analysis, published by Wang et al (2010), evaluated autologous HCT plus further chemotherapy or no further treatment for patients with AML in CR1.44 Nine randomized trials involving 1104 adults who underwent autologous HCT and 1118 patients who received additional chemotherapy or no additional treatment were identified. Analyses suggested that autologous HCT in CR1 is associated with statistically significant reduction of relapse risk (RR=0.56; 95% CI, 0.44 to 0.71; p=0.001) and significant improvement in DFS (HR=0.89; 95% CI, 0.80 to 0.98), but at the cost of an increased nonrelapse mortality rate (RR=1.90; 95% CI, 1.34 to 2.70; p=0.23). There were more deaths during the first remission among patients assigned to autologous HCT than among the chemotherapy recipients or further untreated patients. As a consequence of the increased nonrelapse mortality rate, no statistical difference in OS (HR=1.05; 95% CI, 0.91 to 1.21) was associated with the use of autologous HCT, compared with further chemotherapy or no further therapy. These results are concordant with the earlier meta-analysis.

**Randomized Controlled Trials**

RCTs published after the meta-analyses will be reviewed here.

A prospective, randomized phase 3 trial by Vellenga et al (2011) compared autologous HCT with intensive consolidation chemotherapy among patients (range, 16-60 years) with newly diagnosed AML of similar risk profiles in CR1.45 After 2 cycles of intensive chemotherapy (etoposide and mitoxantrone), patients in CR1 who were not candidates for allo-HCT were randomized to a third consolidation cycle of the same chemotherapy (n=259) or autologous HCT (n=258). The HCT group experienced an upward trend toward superior RFS (38%) compared with the chemotherapy group at 5 years (29%; p=0.065). HCT patients also had a lower relapse rate at 5 years (58%) compared with chemotherapy recipients (70%; p=0.02). OS did not differ between the HCT group (44%) and the chemotherapy group (41%; p=0.86). Nonrelapse mortality rates were higher in the autologous HCT group (4%) than in the chemotherapy consolidation group (1%; p=0.02). Despite this difference in nonrelapse mortality, the relative equality of OS rates was attributed by the investigators to a higher proportion of successful salvage treatments (second-line chemotherapy, autologous or allo-HCT) in the chemotherapy consolidation recipients that were not available to the autologous HCT patients. This large trial has shown an advantage for post-remission autologous HCT in reducing relapse, but similar OS rates secondary to better salvage of chemotherapy-consolidated patients.

Miyamoto et al (2018) reported results of a randomized, multicenter phase III trial comparing autologous HCT versus high-dose cytarabine (HiDAC) consolidation as post-remission therapy AML conducted in 24 centers in Japan from 2003 to 2011.46 240 patients between 15 and 64 years of age
with newly diagnosed favorable- and intermediate-risk AML, with ECOG performance status of < 3 were enrolled; 87 of those who achieved CR1 were randomized to autologous HCT or HiDAC. The study was powered to include 122 patients with 5 years of accrual and 3 years of post-accrual follow-up to detect a difference in DFS at 3 years of 40% versus 65%. Approximately one-third of the patients had favorable risk AML and the remaining two-thirds had intermediate-risk AML. The median age was 48 years. Median follow-up was approximately 4.5 to 5 years. Three-year DFS rate was 41% (95% CI, 27 to 55) in the HiDAC group and 55% (95% CI, 38 to 68) in the autologous HCT group (p=0.25). Three-year OS was 77% (95% CI, 61 to 87) versus 68% (95% CI, 52 to 80) (p=0.67). Cumulative incidence of relapse was 54% versus 41% (p=0.22). There were no differences between the HiDAC and autologous HCT groups in the incidence of liver or renal dysfunction. The incidence of life-threatening infectious complications (p=0.003) and mucositis/diarrhea (p=0.002) was significantly higher in the autologous HCT group.

Section Summary: Autologous HCT for Chemotherapy-Responsive Consolidation

Evidence for the use of autologous HCT for patients with AML who do not have a suitable allogeneic donor or who cannot tolerate an allogeneic procedure consists of several RCTs comparing autologous HCT with chemotherapy and prospective cohort studies. Meta-analyses of these studies and trials were reported improved DFS and relapse but did not find a significant improvement in OS. A potential explanation for this discrepancy between DFS and OS is the increased nonrelapse mortality rate experienced by patients in the transplantation group.

Autologous HCT for Relapsed AML After Chemotherapy

In patients without an allogeneic donor or who are not candidates for allo-HCT due to age or other factors, autologous HCT may achieve prolonged DFS in 9% to 55% of patients in CR2 depending on risk category. However, because it is likely that stem cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, and it is often difficult to achieve CR2 in these patients, autologous HCT in this setting is usually limited to patients who have a sufficient stem cell preparation remaining from the collection in CR1.

Summary of Evidence

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in first complete remission who receive allo-HCT with MAC, the evidence includes RCTs and matched cohort studies. The relevant outcomes are OS and disease-specific survival (DSS). The evidence has revealed that allo-HCT is better at improving OS and DSS rates in patients with AML in first complete remission than conventional chemotherapy. All trials employed natural randomization based on donor availability and intention-to-treat analysis. Survival rates appear to be associated with the presence of MRD and risk category. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in first complete remission who receive allo-HCT with myeloablative conditioning (MAC), the evidence includes randomized controlled trials and matched cohort studies. The relevant outcomes are overall survival (OS) and disease-specific survival (DSS). The evidence has revealed that allo-HCT is better at improving OS and DSS rates in patients with AML in first complete remission than conventional chemotherapy. All trials employed natural randomization based on donor availability and intention-to-treat analysis. Survival rates appear to be associated with the presence of minimal residual disease and risk category. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have AML refractory to standard induction chemotherapy who receive allo-HCT with MAC, the evidence includes retrospective data compiled from patients entered in phase 3 trials and registry data. The relevant outcomes are OS and DSS. The evidence would suggest that allo-HCT improves OS and DSS rates in patients who are refractory to induction chemotherapy better than conventional chemotherapy. While there are some limitations to the evidence, which include its retrospective nature, lack of rigorous randomization, and general pitfalls of registry data, these results may provide a clinically meaningful benefit for patients who do not have other treatment options. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML who relapsed after standard induction chemotherapy-induced first complete remission who receive allo-HCT or autologous HCT with MAC, the evidence includes retrospective data compiled from patients entered in phase 3 trials and registry data. The relevant outcomes are OS and DSS. The evidence has shown that allo-HCT improves OS rates in patients with relapsed AML better than conventional chemotherapy. Limitations of the evidence include its retrospective nature, lack of rigorous randomization, and pitfalls of registry data. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in first complete remission and for medical reasons cannot tolerate MAC who receive allo-HCT with reduced-intensity conditioning, the evidence includes two randomized controlled trials, two meta-analyses, and other comparative and noncomparative studies. The relevant outcomes are OS, DSS, and treatment-related morbidity. The randomized controlled trials compared reduced-intensity conditioning with MAC and reported similar rates in nonrelapse mortality, relapse, and OS though one of the trials was stopped prematurely due to slow accrual of patients. Two retrospective comparative studies found no difference in OS or leukemia-free survival between the conditioning regimens. It appears unlikely that additional comparative evidence will be generated. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML in first complete remission or beyond without a suitable allo-HCT donor who receives autologous HCT, the evidence includes prospective cohort studies in which patients with an available sibling donor were offered allo-HCT (biologic randomization) with random assignment of all others to autologous HCT or chemotherapy (or no further treatment); and randomized trials comparing autologous HCT with chemotherapy in all patients. The relevant outcomes are OS and DSS. Compared with chemotherapy, patients undergoing autologous HCT experienced reduced relapse and improved disease-free survival rates. The OS did not differ between the groups. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Clinical Input from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 1 physician specialty society (2 reviewers) and 1 academic medical center while this policy was under review in 2009. There was a strong consensus among reviewers that allogeneic hematopoietic cell transplantation (HCT) with reduced-
intensity conditioning was of value in patients who were in complete remission. There was general support for the policy statements.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network

The National Comprehensive Cancer Network clinical guidelines (v.2.2018)48 for acute myeloid leukemia state that allogeneic HCT is recommended for patients aged<60 years after standard-dose cytarabine induction with induction failure or significant residual disease without a hypocellular marrow or as post-remission therapy in those with intermediate-risk or poor-risk cytogenetics. It is also recommended for patients aged ≥60 years after standard-dose cytarabine induction with residual disease or induction failure or following complete response (reduced-intensity HCT).

Allogeneic HCT is also recommended for relapsed or refractory disease. For relapsed disease in patients who have a previously identified donor, the guidelines state that chemotherapy followed by allogeneic HCT can be considered but only if ‘the patient has entered remission or in the context of a clinical trial’. Recommendations also include autologous HCT in patients who achieve second molecular remission and to reserve allogeneic transplant for those patients who have persistent disease, despite therapy for the relapsed disease.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services have the following national coverage determination on the use of cell transplantation for acute myeloid leukemia49:

- Allogeneic: “...for the treatment of leukemia, leukemia in remission...”
- Autologous: “Acute leukemia in remission who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched.”

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00342316</td>
<td>Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning versus Best Standard Care in Acute Myeloid Leukemia in First Complete Remission</td>
<td>360</td>
<td>Dec 2017</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

ESSENTIAL HEALTH BENEFITS

The Affordable Care Act (ACA) requires fully insured non-grandfathered individual and small group benefit plans to provide coverage for ten categories of Essential Health Benefits (“EHBs”), whether the benefit plans are offered through an Exchange or not. States can define EHBs for their respective state.
States vary on how they define the term small group. In Idaho, a small group employer is defined as an employer with at least two but no more than fifty eligible employees on the first day of the plan or contract year, the majority of whom are employed in Idaho. Large group employers, whether they are self-funded or fully insured, are not required to offer EHBs, but may voluntary offer them.

The Affordable Care Act requires any benefit plan offering EHBs to remove all dollar limits for EHBs.

REFERENCES


27. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic


**CODES**

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204</td>
<td>Management of recipient hematopoietic cell donor search</td>
</tr>
</tbody>
</table>

Original Policy Date: December 1999
and cell acquisition

38205 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic

38206 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, autologous

38207 Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage

38208 ; thawing of previously frozen harvest, without washing; per donor

38209 ; thawing of previously frozen harvest, with washing; per donor

38210 ; specific cell depletion with harvest, T-cell depletion

38211 ; tumor cell depletion

38212 ; red blood cell removal

38213 ; platelet depletion

38214 ; plasma (volume) depletion

38215 ; cell concentration in plasma, mononuclear, or buffy coat layer

38230 Bone marrow harvesting for transplantation; allogeneic

38232 ; autologous

38240 Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor

38241 ; autologous transplantation

38242 Allogeneic donor lymphocyte infusions

HCPCS Q0083-Q0085 Chemotherapy administration code range

J9000-J9999 Chemotherapy drug code range

S2140 Cord blood harvesting for transplantation, allogeneic

S2142 Cord blood-derived stem-cell transplantation, allogeneic

S2150 Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic, and emergency services)

ICD-10-CM C92.00-C92.02 Acute myeloblastic leukemia code range

C92.40-C92.42 Acute promyelocytic leukemia code range

C92.50-C92.52 Acute myelomonocytic leukemia code range

ICD-10-PCS 30243G0, 30243G1, 30243X0, 30243X1, 30243Y0, 30243Y1 Administration, circulatory, transfusion, central vein, percutaneous, autologous, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list

30243G2, 30243X2, 30243Y2 Administration, circulatory, transfusion, central vein, percutaneous, allogeneic related, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list

30243G3, 30243X3, 30243Y3 Administration, circulatory, transfusion, central vein, percutaneous, allogeneic unrelated, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list

30243G4, 30243X4, Administration, circulatory, transfusion, central vein,
### MP 8.01.26
Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

<table>
<thead>
<tr>
<th>Type of service</th>
<th>Therapy</th>
<th>Place of service</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Inpatient/Outpatient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30243Y4</td>
<td>percutaneous, allogeneic unspecified, code by substance (bone marrow, cord blood or stem cells, hematopoietic) code list</td>
</tr>
</tbody>
</table>

#### POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/14/14</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 18, 2014; references 13 and 35-36 added. No change to policy statements</td>
</tr>
<tr>
<td>08/13/15</td>
<td>Replace policy</td>
<td>Policy updated with literature review through July 9, 2015; no references added. Policy statements updated with clarifying information and to align with other HSCT policies but the intent remains unchanged.</td>
</tr>
<tr>
<td>01/14/16</td>
<td>Replace policy</td>
<td>Policy updated with literature review through December 13, 2015; references 2-3 and 35 added. Policy statements unchanged</td>
</tr>
<tr>
<td>02/24/17</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho annual review; no change to policy.</td>
</tr>
<tr>
<td>07/25/17</td>
<td>Replace policy</td>
<td>Policy updated with literature review through June 2, 2017; references 13, 19, 33, 39, and 41 added. “Stem” removed from title and policy. HSCT changed to HCT in Policy and Policy Guidelines. Policy statements otherwise unchanged.</td>
</tr>
<tr>
<td>01/30/18</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted. Policy updated with literature review through November 6, 2017; references 16-17 and 49-51 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>08/20/18</td>
<td>Replace policy</td>
<td>Duplicate citation of reference 31 removed.</td>
</tr>
<tr>
<td>01/24/19</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, effective 01/24/2019. Policy updated with literature review through October 30, 2018; reference 48 added. Policy statement regarding medical necessity for auto-HCT changed to clarify that it applies to patients that are not candidates for allo-HCT. Investigational statements added for patients not meeting MN criteria.</td>
</tr>
</tbody>
</table>

Original Policy Date: December 1999